About Acceleron Pharma
Acceleron Pharma is a company based in Cambridge (United States) founded in 2004 was acquired by Merck in September 2021. Acceleron Pharma has raised $137.67 million across 9 funding rounds from investors including Merck, Bessemer Venture Partners and Alkermes. Acceleron Pharma offers products and services including Vaccines and Medicines.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Merck & Co., Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acceleron Pharma
Acceleron Pharma offers a comprehensive portfolio of products and services, including Vaccines and Medicines.
Develops vaccines for infectious diseases and prevention.
Provides treatments for oncology and other disorders.
People of Acceleron Pharma
Unlock access to complete
Unlock access to complete
Leadership Team
442 people
Software Development Team
251 people
Product Management Team
73 people
Sales and Marketing
73 people
Senior Team
64 people
Data Analysis and Operations Team
63 people
Operations Team
54 people
Finance and Accounting
30 people
Unlock access to complete
Funding Insights of Acceleron Pharma
Acceleron Pharma has successfully raised a total of $137.67M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Acceleron Pharma
Acceleron Pharma has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Bessemer Venture Partners and Alkermes.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm making investment in early stage startups in the US
|
Locked | Locked | Locked | |
|
Seed and early-stage venture capital is provided to US companies.
|
Locked | Locked | Locked | |
|
Venture capital investments and support for entrepreneurs in technology and innovation sectors.
|
Locked | Locked | Locked |
Investor details for Acceleron Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acceleron Pharma
Investment portfolio details for Acceleron Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Acceleron Pharma
Detailed financials for Acceleron Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acceleron Pharma Comparisons
Peer comparison for Acceleron Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Acceleron Pharma
Detailed competitors of Acceleron Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acceleron Pharma
Complete news archive for Acceleron Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acceleron Pharma
Acceleron Pharma was founded in 2004.
Acceleron Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Acceleron Pharma is a funded company, having raised a total of $137.67M across 9 funding rounds to date.
Acceleron Pharma is a developer of protein therapeutics to treat cancer and rare blood disorders. The company is developing luspatercept and sotatercept therapeutic candidates to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes. The sotatercept therapeutic candidate is also used to increase bone mineral density, and to treat the final stage of chronic kidney disease and end-stage renal disease. It is also developing a dalantercept therapeutic candidate to treat renal cell carcinoma, hepatocellular carcinoma, and ACE-083 that is in Phase 1 clinical trial used to promote muscle growth and function in specific treated muscle groups.
Acceleron Pharma offers Vaccines and Medicines.
Acceleron Pharma has 12 investors. Key investors include Merck, Bessemer Venture Partners, Alkermes, Flagship Pioneering, and Orbimed.